Lyme Disease and the Need for Advanced Diagnostics

Lyme disease, caused by the spirochete bacterium Borrelia burgdorferi and transmitted through the bite of infected black-legged ticks, remains one of the most challenging infectious diseases to diagnose and manage. The early symptoms—fever, headache, fatigue, and the characteristic erythema migrans rash—can be mistaken for other conditions. If left untreated, the infection can spread to the joints, heart, and nervous system, leading to chronic arthritis, carditis, and neurological deficits. Accurate diagnosis is therefore critical, yet conventional methods fall short in many scenarios. Emerging imaging modalities are now offering a window into the living body that could transform how clinicians detect, localize, and monitor Lyme disease.

Limitations of Traditional Diagnostic Methods

For decades, the cornerstone of Lyme disease diagnosis has been serological testing using a two‑tier algorithm. This starts with an enzyme immunoassay (EIA) or immunofluorescence assay, followed by a Western blot if the first test is positive or equivocal. While these tests have reasonable sensitivity in later stages, they perform poorly during early infection when antibody levels are low. False negatives are common in the first few weeks, and false positives can occur due to cross‑reactivity with other spirochetes, autoimmune conditions, or previous infections. Serology also cannot distinguish active infection from past exposure, making it difficult to assess treatment success.

Polymerase chain reaction (PCR) for Borrelia DNA in blood or joint fluid offers improved specificity but suffers from low sensitivity except in synovial fluid from Lyme arthritis patients. Culture of the organism is the gold standard but is slow, requires specialized media, and has low yield. As a result, there is a pressing need for diagnostic tools that can directly visualize the presence of the pathogen or the inflammatory response it triggers in tissues. Imaging technologies are emerging to fill this gap.

Emerging Imaging Modalities

Advanced Magnetic Resonance Imaging (MRI)

Conventional MRI is already used to assess Lyme arthritis and neuroborreliosis, but advanced techniques are now providing far greater detail. Diffusion‑weighted imaging (DWI) and diffusion tensor imaging (DTI) can detect microstructural changes in the brain and spinal cord even when standard sequences appear normal. In patients with Lyme encephalopathy, DTI reveals reduced fractional anisotropy in white matter tracts, correlating with cognitive dysfunction. Contrast‑enhanced MRI using gadolinium can identify meningeal enhancement and cranial nerve inflammation, hallmarks of early neuroborreliosis.

Magnetic resonance spectroscopy (MRS) adds a metabolic dimension, measuring levels of N‑acetylaspartate, choline, and other metabolites. Studies have shown altered metabolite ratios in the basal ganglia and thalamus of patients with chronic Lyme disease, suggesting neuronal loss or dysfunction. These techniques are particularly valuable for differentiating Lyme‑related neurological changes from multiple sclerosis or other inflammatory conditions. Researchers are also exploring ultra‑high‑field MRI (7 Tesla) to achieve sub‑millimeter resolution of perivascular spaces and micro‑infarcts that may harbor Borrelia organisms.

Positron Emission Tomography (PET)

PET imaging provides functional information by tracing metabolic activity or specific molecular targets. The most common tracer, [¹⁸F]‑fluorodeoxyglucose (FDG), accumulates in cells with high glucose uptake, such as activated immune cells. In Lyme disease, FDG‑PET has been used to identify sites of active inflammation in joints, lymph nodes, and the brain. For instance, a 2021 study demonstrated increased FDG uptake in the medial temporal lobes and thalamus of patients with Lyme encephalopathy, regions associated with memory and executive function.

Novel tracers are being developed to target inflammation more specifically. [¹¹C]‑PK11195 binds to translocator protein (TSPO) expressed on activated microglia and macrophages, offering a marker of neuroinflammation. Preclinical models suggest that such tracers can detect early Borrelia‑induced neuroinflammation before structural damage occurs. Other experimental tracers target the Borrelia surface protein OspA or the perivascular immune complexes that form in Lyme carditis. While still in early phases, these approaches could allow clinicians to pinpoint active infection and differentiate it from post‑treatment Lyme disease syndrome (PTLDS).

Single‑Photon Emission Computed Tomography (SPECT)

SPECT is more widely available than PET and uses radiotracers such as [⁹⁹mTc]‑HMPAO to measure cerebral blood flow. Several studies have found hypoperfusion in the frontal, temporal, and parietal lobes of Lyme disease patients with cognitive complaints. Although SPECT lacks the spatial resolution of PET, serial scans can be used to monitor changes in regional perfusion over the course of treatment. Reduced perfusion in the white matter may correlate with persistent symptoms even after standard antibiotic therapy, raising questions about ongoing vascular dysfunction or inflammation.

Ultrasound and High‑Frequency Sonography

Ultrasound is a non‑invasive, low‑cost modality that can image superficial structures such as joints, tendons, and peripheral nerves. In Lyme arthritis, high‑frequency ultrasound (10‑18 MHz) can detect synovitis, effusions, and enthesitis with high sensitivity. Power Doppler imaging reveals increased blood flow in inflamed synovia, providing a semiquantitative measure of disease activity that can help guide treatment decisions. Peripheral neuroborreliosis can also be evaluated: the tibial and sural nerves may show increased cross‑sectional area and fascicular swelling on ultrasound, a pattern distinct from other neuropathies.

Newer contrast‑enhanced ultrasound techniques using microbubbles could further improve the detection of subtle inflammation in soft tissues. Although not yet validated for Lyme disease, these methods hold promise for identifying active disease foci in patients with atypical symptoms.

Optical Imaging and Experimental Approaches

On the research frontier, optical imaging techniques such as near‑infrared fluorescence (NIRF) are being investigated in animal models. By coupling fluorescent dyes to antibodies against Borrelia surface antigens, researchers can visualize spirochetes in living mice using whole‑body imaging systems. While this is far from clinical application, it demonstrates the potential for molecular imaging to provide real‑time, pathogen‑specific detection. Multiphoton microscopy can also track the movement of fluorescently labeled immune cells in tissues, offering insights into the dynamics of the host response.

Clinical Applications of Advanced Imaging

Early Detection and Differential Diagnosis

Imaging can be especially valuable in the early stages of Lyme disease when serology is unreliable. In patients presenting with neurological symptoms, a positive PET or MRI finding in the brainstem or cranial nerves may prompt earlier initiation of antibiotics, even before laboratory confirmation. Similarly, in patients with an atypical rash or joint symptoms, ultrasound findings of synovitis with a particular pattern can raise suspicion for Lyme arthritis rather than osteoarthritis or rheumatoid arthritis. The ability to visualize inflammation directly reduces diagnostic delays and the risk of progression to late‑stage disease.

Monitoring Treatment Response

One of the greatest challenges in Lyme disease management is assessing whether treatment has eradicated the infection. Persistent symptoms are common, but it is often unclear whether they represent ongoing active infection, post‑infectious autoimmunity, or tissue damage. Serial imaging can help. For example, a decline in FDG‑PET uptake in affected joints or brain regions after antibiotic therapy suggests a resolution of active inflammation. Conversely, stable or increasing uptake may indicate treatment failure, prompting a switch to alternative regimens. MRS can also monitor neuronal recovery over months, providing objective biomarkers of healing.

Guiding Biopsy and Targeted Interventions

In rare cases where infection is suspected in deep tissues such as the myocardium or pericardium, imaging can guide biopsy to confirm the diagnosis. PET‑CT has been used successfully to localize sites of suspected Lyme carditis and direct endomyocardial sampling. Similarly, in patients with Lyme neuroborreliosis who do not respond to treatment, advanced MRI may identify abscesses or granulomas that require surgical drainage. Accurate localization not only improves diagnostic yield but also reduces the need for invasive diagnostics.

Challenges Facing Imaging‑Based Diagnosis

Despite their promise, these imaging modalities are not without obstacles. Cost is a major barrier: PET and high‑field MRI are expensive and not universally accessible. Many healthcare systems cannot afford to scan every patient with suspected Lyme disease. Furthermore, imaging findings in Lyme disease are often nonspecific. For instance, white matter hyperintensities on MRI can be caused by migraines, aging, small‑vessel disease, or multiple sclerosis. Without highly specific tracers or pathognomonic patterns, false‑positive interpretations are possible.

Another challenge is the lack of standardized protocols. Different institutions use different scanners, sequences, and tracers, making it difficult to compare results across studies. The field would benefit from consensus guidelines on when and how to use imaging in Lyme disease. Additionally, radiation exposure from PET and SPECT limits their use in children and pregnant women, who may be more vulnerable.

Finally, validation studies are urgently needed. Most of the evidence for imaging in Lyme disease comes from small case series or retrospective analyses. Large, prospective, multicenter trials comparing imaging outcomes with clinical and serological endpoints are necessary to establish sensitivity, specificity, and positive predictive value. Without such data, insurance companies and clinicians may be reluctant to incorporate imaging into routine care.

Future Directions

Artificial Intelligence and Advanced Image Analysis

Machine learning algorithms can be trained to recognize subtle patterns in imaging data that are invisible to the human eye. Deep learning models applied to brain MRI have already shown promise in distinguishing neuroborreliosis from other inflammatory brain diseases based on texture and morphometric features. As larger datasets become available, AI could automate the screening of scans and flag suspicious findings, reducing radiologist workload and improving diagnostic consistency. Integration of imaging data with clinical and laboratory parameters via multimodal deep learning may further raise diagnostic accuracy.

Development of Lyme‑Specific Tracers

Efforts are underway to design tracer molecules that bind directly to Borrelia burgdorferi or to immune complexes unique to the disease. If successful, such tracers would provide near‑absolute specificity, overcoming the current limitation of nonspecific inflammation signals. Antibodies, peptides, and small molecules targeting the bacterial flagellin, outer surface proteins, or the tick salivary antigens that persist after the bite are all under investigation. In animal models, radiolabeled antibodies have already been used to detect Borrelia in joints and heart tissue. Clinical translation will require safety studies and Good Manufacturing Practice (GMP) compliance.

Multimodal Imaging and Theranostics

Combining structural, functional, and molecular imaging into a single session could provide a comprehensive picture of the disease. For example, simultaneous PET‑MRI can reveal both anatomical damage and metabolic activity in the same region. Hybrid systems are already being installed in many academic centers. The same tracer used for diagnosis could also be conjugated with a therapeutic payload (e.g., a radionuclide for targeted radiotherapy or an antibiotic that accumulates at infected sites), creating a theranostic approach. While this idea is speculative, it represents the ultimate vision of precision medicine for infectious diseases.

Conclusion

Imaging is evolving from an adjunct tool to a potential mainstay in the diagnosis and monitoring of Lyme disease. Advanced MRI, PET, SPECT, and ultrasound each offer unique windows into the inflammatory and structural changes caused by Borrelia burgdorferi. Early evidence suggests that these modalities can improve detection in seronegative patients, guide treatment decisions, and provide objective endpoints for clinical research. Overcoming the current challenges of cost, specificity, and validation will require concerted effort from clinicians, researchers, and industry. As the field moves forward, the integration of novel tracers, artificial intelligence, and multimodal hardware promises to make imaging an indispensable component of Lyme disease care.

For those seeking further details, the CDC Lyme Disease page provides core clinical information. A thorough review of PET imaging in Lyme neuroborreliosis and advanced MRI findings in Lyme encephalopathy can be found in peer‑reviewed journals. The latest consensus on imaging in infectious diseases offers additional context for these emerging modalities.